Eagle Pharmaceuticals (EGRX) – Analysts’ Weekly Ratings Changes

Eagle Pharmaceuticals (NASDAQ: EGRX) has recently received a number of price target changes and ratings updates:

  • 10/14/2019 – Eagle Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $67.00 price target on the stock. According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “
  • 10/10/2019 – Eagle Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “
  • 10/8/2019 – Eagle Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 10/2/2019 – Eagle Pharmaceuticals was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 9/19/2019 – Eagle Pharmaceuticals was upgraded by analysts at TheStreet from a “c+” rating to a “b-” rating.
  • 8/28/2019 – Eagle Pharmaceuticals was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 8/16/2019 – Eagle Pharmaceuticals was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.

Shares of NASDAQ EGRX traded up $1.26 during trading hours on Tuesday, reaching $61.99. 128,319 shares of the stock were exchanged, compared to its average volume of 176,884. The firm has a market capitalization of $835.65 million, a price-to-earnings ratio of 29.66 and a beta of 1.41. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.36 and a current ratio of 3.59. Eagle Pharmaceuticals Inc has a 52 week low of $36.03 and a 52 week high of $62.98. The stock’s fifty day simple moving average is $57.36 and its 200 day simple moving average is $54.42.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $0.48 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.17. The company had revenue of $56.70 million for the quarter, compared to analyst estimates of $53.61 million. Eagle Pharmaceuticals had a return on equity of 24.10% and a net margin of 19.79%. The firm’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.99 earnings per share. Research analysts predict that Eagle Pharmaceuticals Inc will post 2.52 EPS for the current fiscal year.

In other news, Director Hudson Executive Capital Lp sold 1,112 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $60.06, for a total transaction of $66,786.72. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last quarter, insiders have sold 6,113 shares of company stock worth $367,386. 31.70% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in EGRX. Marshall Wace North America L.P. increased its stake in Eagle Pharmaceuticals by 57.8% during the 1st quarter. Marshall Wace North America L.P. now owns 5,956 shares of the specialty pharmaceutical company’s stock worth $301,000 after acquiring an additional 2,182 shares during the period. WINTON GROUP Ltd bought a new position in Eagle Pharmaceuticals during the 2nd quarter worth $314,000. Scout Investments Inc. increased its stake in Eagle Pharmaceuticals by 79.7% during the 2nd quarter. Scout Investments Inc. now owns 98,810 shares of the specialty pharmaceutical company’s stock worth $5,502,000 after acquiring an additional 43,815 shares during the period. Louisiana State Employees Retirement System bought a new position in Eagle Pharmaceuticals during the 2nd quarter worth $206,000. Finally, Foundry Partners LLC increased its stake in Eagle Pharmaceuticals by 865.6% during the 2nd quarter. Foundry Partners LLC now owns 73,385 shares of the specialty pharmaceutical company’s stock worth $4,086,000 after acquiring an additional 65,785 shares during the period. Institutional investors own 97.51% of the company’s stock.

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

See Also: Arbitrage

Receive News & Ratings for Eagle Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.